Explore how the rare disease landscape continues to be transformed by innovations in science, drug development and connectivity.
The need for impactful and clear communication has never been greater, which is why we put Science brought to life at the heart of everything we think, feel and do.
Read moreExplore how the rare disease landscape continues to be transformed by innovations in science, drug development and connectivity.
Explore how biotechs can navigate their first commercialisation in Europe, overcoming market fragmentation, pharma giants, resource constraints and regulatory hurdles to achieve a successful launch.
In this report, we reveal industry predictions for the rare disease landscape in 2034 and explore key approaches that show great promise, including gene therapies, artificial intelligence, whole-genome screening and personalised treatment, before assessing what the top priorities should be over the next decade to improve patient care.
Unlock the full potential of Medical Affairs teams in the pharmaceutical industry to address complex challenges and lead strategic decision-making.
Discover the value of patient-reported outcomes (PROs) in clinical trials and how they can help address unmet needs in ovarian cancer.
Malcolm Badger, our Chief Creative Officer, shares valuable insight into how Cognite engages
healthcare professionals by infusing science with emotion – thereby bringing it to life.
Our CBO, Sean Cush, explains how the Medical Affairs function has evolved to become one of the pivotal, strategic parts of pharmaceutical and biotech companies.
Members of our senior management team outline the strengths of our Medical Affairs offer.
Our Principal Principal Copywriter, Andy Baker, tests the accuracy of AI tool ChatGPT when writing medical copy.
Our chief scientific officer, Stephanie Westwood, summarises the attributes required to be able to bring science to life.